治験レーダーAI
治験 NCT07270016 (REFLECT2DPilot)(対象:2型糖尿病、高血糖、身体不活動、Lifestyle (Sedentary Behavior and Physical Activity)、持続血糖モニタリング)は募集中です。詳細は治験レーダーのタイル表示と AI 発見ツールで確認するか、ここで質問してください。
フィルター基準に一致する試験が1件見つかりました
タイル表示

Pilot-Testing Real-Time Engagement for Learning to Effectively Control Type 2 Diabetes (REFLECT2DPilot) 30 食事療法

募集中
治験(臨床試験)の詳細は主に英語で提供されていますが、治験レーダーAIがサポートします!「治験解説」をクリックして、選択した言語で試験情報を表示し、議論してください。
治験番号 NCT07270016 (REFLECT2DPilot) は 介入研究 臨床試験 で、2型糖尿病、高血糖、身体不活動、Lifestyle (Sedentary Behavior and Physical Activity)、持続血糖モニタリング に関するものです。現在は 募集中 で、2026年2月16日 から開始しています。30 名の参加者 の募集が計画されています。この試験は ピッツバーグ大学 によって主導され、2026年12月1日 に完了予定です。ClinicalTrials.gov からの最新更新日は 2026年2月20日 です。
概要
The goal of this study is to pilot test features of a new smartphone app and to gather feedback related to wearing a continuous glucose monitor (CGM) and a Fitbit device, as well as to obtain input on health behavior-focused messages delivered through the app. The study will enroll English-speaking participants aged 16-24 years who were diagnosed with type 2 diabetes before age 18. Participants will be asked to fill ...もっと見る
公式タイトル

Real-Time Engagement for Learning to Effectively Control Type 2 Diabetes: Pilot Study

疾患名
2型糖尿病高血糖身体不活動Lifestyle (Sedentary Behavior and Physical Activity)持続血糖モニタリング
その他の研究識別子
NCT番号
開始日
2026-02-16
最終更新日
2026-02-20
終了予定日
2026-12
目標参加者数
30
試験の種類
介入研究
治験の相・段階
該当なし
状況
募集中
キーワード
adolescent
young adult
type 2 diabetes
CGM
主目的
その他
割付方法
該当なし
介入モデル
単一群割当
盲検化
なし(非盲検)
群(アーム)/介入
参加グループ/群介入/治療法
実験的Single-arm pilot study
Participants will engage in pilot-testing a novel smartphone app supporting health behavior change and wear a continuous glucose monitoring device and Fitbit physical activity tracker for 30 days. Questionnaires and interviews will be used to gather participant experiences with the app and device wear.
Healthmine app
Participants will wear study-provided continuous glucose monitoring device and Fitbit physical activity tracker for 30 consecutive days. During the same period, they will use an investigator-developed smartphone app (Healthmine), which is being developed to pair CGM and Fitbit data. Participants will receive up to one message about health behavior change (e.g., physical activity, nutrition) daily and will be able to ...もっと見る
主要評価項目
評価指標指標の説明時間枠
Usability of Healthmine app
Assessed via the System Usability Scale (SUS), a 10-item questionnaire measuring perceived usability of a system or technology. Each item is rated on a 5-point Likert scale ranging from 1 ("strongly disagree") to 5 ("strongly agree"). The total SUS score is calculated by summing the score contributions from each item (for odd-numbered items, subtract 1 from the user response; for even-numbered items, subtract the user response from 5), multiplying the sum by 2.5, resulting in a score ranging from 0 to 100. Higher scores indicate better perceived usability, with scores above 68 considered above average usability.
15 days and 30 days after starting study-provided CGM and Healthmine app use
副次評価項目
評価指標指標の説明時間枠
Days with CGM data
The number of days with continuous glucose monitoring data available will be divided by the total number of requested days of wear (30) to obtain percentage of days with data.
30-day CGM wear period
Days with Fitbit data
The number of days with Fitbit data available will be divided by the total number of requested days of wear (30) to obtain percentage of days with data.
30-day Fitbit wear period
Mean CGM glucose
Mean glucose obtained from study-provided CGM
30-day CGM wear period
Step count
Step count data will be obtained via study-provided Fitbit.
30-day Fitbit wear period
Diabetes Self-Management
Assessed via the Diabetes Self-Management Questionnaire (DSMQ), a 16-item self-report questionnaire measuring diabetes self-care activities associated with glycemic control. Each item is rated on a 4-point Likert scale (0 = "does not apply to me" to 3 = "applies to me very much"). Items are summed (after reverse-coding negatively worded items) and transformed to a 0-10 scale, where higher scores indicate better self-management.
Baseline and 30 days (change from baseline to 30 days)
Treatment Self-Regulation
Assessed via the Treatment Self-Regulation Questionnaire (TSRQ), a questionnaire measuring the degree to which a person's motivation for health behaviors is relatively autonomous (self-determined) versus controlled (motivated by external factors). Items are rated on a 7-point Likert scale (1 = "not at all true" to 7 = "very true"). The TSRQ yields subscale scores for autonomous regulation, controlled regulation, and amotivation, with higher scores on each subscale indicating greater levels of that type of motivation.
Baseline and 30 days (change from baseline to 30 days)
Self-Reported Physical Activity
Assessed via the PACE+ Physical Activity Measure, a brief self-report questionnaire measuring physical activity levels. Participants report the number of days per week they engage in moderate or vigorous physical activity for at least 30 minutes (or 60 minutes for adolescents). The measure yields separate scores for moderate and vigorous activity (each ranging from 0-7 days per week), with higher scores indicating greater physical activity frequency.
Baseline and 30 days (change from baseline to 30 days)
Diet Quality
Assessed via the Prime Diet Quality Score (PDQS), a food-based dietary assessment tool that evaluates diet quality across 15 food group components. The PDQS includes 10 adequacy components (dark green leafy vegetables, cruciferous vegetables, carrots, other vegetables, citrus fruits, other fruits, fish/seafood, eggs, whole grains, and low-fat dairy) and 5 moderation components (red meat as main dish, processed meat, refined grains and baked goods, sugar-sweetened beverages, and fried foods). Each component is scored based on consumption frequency, with higher scores indicating greater intake of health-promoting foods and lower intake of foods that should be consumed in moderation. The total PDQS ranges from 0-30, with higher scores indicating better overall diet quality.
Baseline and 30 days (change from baseline to 30 days)
Glucose monitoring satisfaction
Assessed via the Glucose Monitoring Satisfaction Survey (GMSS) for Type 2 Diabetes, a 15-item questionnaire measuring patient satisfaction with their glucose monitoring device. Items are rated on a 5-point Likert scale (1 = "strongly disagree" to 5 = "strongly agree"). The GMSS yields four subscale scores: Openness (items 1, 8, 10, 14), Emotional Burden (items 2, 5, 9, 13), Behavioral Burden (items 3, 6, 11, 15), and Worthwhileness (items 4, 7 \[reverse coded\], 12). Subscale scores are calculated as the mean of item responses, with higher scores indicating greater openness, greater burden (for burden subscales), and greater worthwhileness, respectively. A total satisfaction score is calculated as the mean of all items after reverse-coding items 2, 3, 5, 6, 7, 9, 11, 13, and 15, with higher total scores indicating greater overall satisfaction with glucose monitoring.
30 days (following CGM wear period)
Glucose coefficient of variation
Based on CGM glucoses, coefficient of variation will be calculated by dividing the standard deviation of glucose readings by the mean glucose level, then multiplying by 100 to get a percentage.
30-day CGM wear period
Glucose time below range
Percent of time with CGM glucose less than 70 mg/dL
30-day CGM wear period
Glucose time in range
Percent of time with CGM glucose 70-180 mg/dL
30-day CGM wear period
Glucose time above range
Percent of time with CGM glucose above 180 mg/dL
30-day CGM wear period
Mean amplitude of glycemic excursions
A measure of glucose variability calculated from CGM data, calculated by dividing the standard deviation of glucose readings by the mean glucose level, then multiplying by 100 to get a percentage.
30-day CGM wear period
参加アシスタント
適格基準

対象年齢
小児, 成人
試験の最低年齢
16 Years
対象性別
全て
  • Ages 16-24 years, any sex or gender
  • Diagnosis of type 2 diabetes in childhood (younger than 18 years of age)
  • English-speaking (app in English)
  • Possession of personal smartphone that is compatible with FreeStyle Libre app

• Cognitive impairment or severe psychiatric conditions that could interfere with participation in behavioral intervention for diabetes self-management
責任者
Mary Ellen Vajravelu, MD, 主任研究者, Assistant Professor, University of Pittsburgh
試験中央連絡先
連絡先: Mary Ellen Vajravelu, MD, MSHP, 4126926533, [email protected]
1 1カ国の場所

Pennsylvania

Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, 15224, United States
Mary Ellen Vajravelu, MD, MSHP, 連絡先, 412-692-6533, [email protected]
Ana Diaz, RN, 連絡先, 412-692-6862, [email protected]
募集中